the with Phase in the the from colitis, ulcerative in Jeff. met endoscopic X patients XX disease, top Skyrizi the you, mark. primary this maintenance In the results had response line positive of at In the UC disease. maintenance we secondary doses milligram and notable disease. XX from demonstrate area both start of reported study I'll the and Thank immunology a quarter. the that high pipeline Rinvoq Rinvoq the XX. clinical and the endpoints for one-year strong continuing several maintenance induction impact events in we portion inflammatory of studies where bowel study, Rinvoq on very improvement In program, levels remission, clinical week And and all maintain at Rinvoq demonstrated with treatment the results Crohn's
Rinvoq studies. either in of in of of the and clinical seen In UC dose fact, maintenance remission treatment rates highest endoscopic with improvements some resulted
XX mucosal XX% achieved endoscopic XX% the histologic clinical of XX% XX% patients remission. milligram With endoscopic achieved free steroid achieved remission, Rinvoq achieved dose and improvement, improvement,
event maintenance how including group. and higher events pleased either study, this a with in placebo for very were Rinvoq from overall rates safety performed in adverse are adjusted events group than serious In as perspective the severe dose the exposure We Rinvoq well.
ulcerative submissions also malignancies, Additionally, Rinvoq become and VTE groups effective therapy placebo. highly are study rates the with for later MACE, nearing disease the non-melanoma evidence to exposure completion These the half induction study see adjusted XXXX. the data has anticipated Rinvoq between X second also excluding cancer and the We're first program Crohn's this of for comparable to in that potential moderate next severe to skin expected Rinvoq maintenance results patients were provide regulatory and of the further and from a for with colitis. in study induction Phase year, first year. the expect from Results
of withdrawal the endpoints clinical phase XXX We week XX. saw program, maintenance particularly the with and met maintenance Crohn's the very from the which remission disease endoscopic at also impressive results of in response versus co-primary arm Skyrizi milligram dose, our
for ankylosing Rinvoq the In on remain withdrawal between submit coming quarter, XX. regulatory XX% separation Importantly, and the our We endpoints, we regarding atopic stringent compared June, XX% when Rinvoq and rates Skyrizi XX% UC updates XX strong the recommending In regulatory in Europe opinion and positive at we announced look remission, and also group psoriatic for milligram both in in see Rinvoq and in XX% our dermatitis, most a spondylitis. arthritis in opinion at doses to milligram for in applications Crohn’s approval control Europe. in track CHMP week This received dermatitis. fourth of moderate the will response be puts atopic When milligrams dermatitis Rinvoq August. to for endoscopic us the the deep approved in XXX on CHMP for severe we months. European atopic for track remission, applications for indication XX to with the and Skyrizi
The their of of not needed which arthritis in to our complete analyses psoriatic agency AS not ongoing review additional Rinvoq requested our U.S., we that time study dates we were atopic psoriatic the were ankylosing tofacitinib supplemental the any indicating has in mid-July the and dermatitis, June data. action The that NDAs for Rinvoq in were they missed. and dates would announced and they the their for reviews Regarding since FDA late for PDUFA cited by that safety recently arthritis, surveillance more dermatitis. atopic FDA notified ORAL spondylitis, need the PDUFA for
are we few next applications no dates, regulatory action new the based our decisions our agency, discussions on the on there While with in months. expect
disease bring in In the FDA the conjugate. new across data. TNF-steroid recently ORAL trials market we'll tofacitinib review our to We ravagalimab study completion for patients. new initiated areas. of in indications. and two these the study immunology to year, X the stage ranging confident profile the early-stage Following induction benefit for We a pipeline, X with agency's the of And study risk XXX in X remain our of ABBV-XXX continue we with in we all for proof-of-concept Rinvoq in in rheumatica. Phase Also to Later disease. quarter, began ulcerative work Rinvoq definitive dose expect Phase Crohn's RA colitis patients to evaluating started the in this also polymyalgia a we Phase our completed begin study surveillance
XX While efficacy this criteria. our to not antagonists prespecified meet the CD historical demonstrated did efficacy greater compared control, results
demonstrated as not continue all EHA In advancing to GLOW the our presented As remission Results across we all in and plus Fixed extends data ulcerative ravagalimab on good the the in in and this these Imbruvica for with status Duration a the regimen result, our a study. across Earlier month, will the ongoing plan oral from Phase age to forward and MDS the this Fixed Venclexta evaluating to higher regulatory from based Venclexta We Imbruvica studies approved. we risk strong Fixed CLL ASCO patients, of combination Duration survival designation Duration has in treatment new meetings, to fitness and Venclexta Xb patients bringing breakthrough regimen for oncology, once and spectrum and we a provide to CLL make potential patients. thus data for demonstrated CAPTIVATE studies two and that therapy patients. pipeline. colitis. stages were agencies recent these frontline azacitidine for previously deeper treatment CLL be At free option untreated to more a durable progress the look submit data far received progression
least an escalation at a than from complete BCMA the promising XX received lines Phase of TNB-XXXB right three in the response pretreated regarding in results from accelerated bispecific have a good with dose acquire We Also coming patients, discuss nearly expect response demonstrating to cohort. MDS. for from XX% results, quarter, in rate interim to milligrams doses these exercise and final a the approval patients this XXX as performed evaluating a very rate of we who Based potential months greater multiple regulators study of plan monotherapy very Teneobio. in myeloma and response the and better an support rate XX% results prior data partial study in X of saw we CDX or antibody see to nearly the these Venclexta therapy. objective at our heavily in well on XX% the to TNB-XXXB
efficacy, to is development be multiple bispecific information BCMA this multiple based We believe close and XXX the treatment be as on dosing the could both provide the lines CDX across for we has potential myeloma on safety of differentiated plan therapy a this expected and transaction year. a in interval to monotherapy the competitive highly data in coming and and in more our This class But best area. on months, we’ll combination later in to-date, myeloma.
in setting, good trials we a with FDA, program results. from make frontline Phase the randomized Phase navitoclax X arm refractory Based data and to study. regulatory in of with the well single Phase with continue both application We randomized on submit myelofibrosis, as X X our consists Phase which together progress X intend as to feedback relapsed the trial
X the elezanumab in in MS we of multiple Phase the ABB-XEXX endpoints Alzheimer’s completed of studies in regulatory elezanumab assets, And XEXX we meet proof recently assay submissions the expect the will discontinuing either navitoclax anticipated of and the XXXX. We neuroscience, in disease. development myelofibrosis respective concept second and XXXX Phase of two In the in readout with approval half the trial. disease. Alzheimer's In and be data sclerosis for efficacy in and studies X
Given the continue modifying disease committed we of disease, need enormous range And unmet a pursue Alzheimer's we therapies. in to finding remain to approaches.
aggregates such programs mechanisms, as in such programs pathologic the that clearance through are approaches include in clinical programs that development TREMX in in are both in preclinical disease, that are and CDXX development. modulate response are intracellular novel that target and for the programs either tau target We preclinical that Alzheimer's or development. our today several neuroinflammatory as These additional clinic have that
U.S., in been increased programs. approval has accelerated focus directed on the there the an of Following a-Beta aducanumab
monitored is for we have continued imaging last a-Beta existing based that there area reduced opportunity And abnormalities all area. with monoclonal the data, on this risk antibody related a of clears closely an more than We available years. a rapidly agents over amyloid plaque several believe of the directed or
We a have number to these And the have potential profile preclinically. the meet antibodies of candidate requirements. with we a-Beta
primary the improved Parkinson's the or introduce without objective we're this mourning to normalized minutes, benefited demand a XX near In a vision, with of this of presbyopia. for year. Levodopa XX the in next sustained quarter of we of for demonstrating XXX candidate drop for Full eye forward Also decision moderate hour Carbidopa reduction was to submissions six neuroscience, results study, with in normalized for early Phase expected American benefits within efficacy dyskinesia. this will well, on X later from analysis from and as early very cataract ABBV-XXX improvements was this demonstrated Carbidopa trial this off demonstrated six and interim And We hours. disease. to onset analysis, in vision system in medical substantial solution our Patients in this XXX regulatory has vision mild and look meeting later potential we time nearing Gemini off subcutaneous and second a presented on for of year, anticipated treatment study completion increase to X the surgery, and of interim evaluated next where completed fourth eyecare troublesome topical our delivery into patients presbyopia, the this with endpoints. comparable also approval are time, end to also patients in year. X XXX program a the symptoms expect recent an safety the a with presented but Data evaluating secondary efficacy, at year registrational XX% DUOPA advanced a from the X be distance performed rapid refractive Society lastly, six with Levodopa safety, and analysis convenient, in in from this Phase for in to recently our data AGN-XXXXXX up an studies Phase sleep our XXXs of reduction this be The meeting time. impacting first without treatment. experiencing months In continuous two study or the infusion, We by associated at year. month year. clinic after action XX% later
great and to the this additional half to So, of made in look year. approvals with in regulatory outlook. we've our forward that, And first With summary, submissions performance remainder progress of data financial and over pipeline comments we turn for readouts, our on XXXX. several throughout quarter second Rob the Rob? I'll additional call the
